Clinical Trials

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

Number: NCT00579514
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

Number: NCT01802346
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Number: NCT02266745
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Promontory Therapeutics Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can

Number: NCT02484404
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression

Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Number: NCT02635672
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Vincerx Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Number: NCT02649790
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Karyopharm Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors

Number: NCT02717156
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041

Number: NCT02826382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Five Eleven Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Number: NCT02861573
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Merck Sharp & Dohme LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s):
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Number: NCT03012321
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Northwestern University|AstraZeneca|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Number: NCT03016741
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): Northwestern University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

Number: NCT03073395
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Five Eleven Pharma, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Number: NCT03089203
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Pennsylvania
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide⢠Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Number: NCT03129139
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Minneamrita Therapeutics LLC|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s):
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Number: NCT03232164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Wisconsin, Madison
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cisplatin in Castration Resistant Prostate Cancer

Number: NCT03275857
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Rochester|Roswell Park Cancer Institute
Sponsor Trial Information
Trial Location(s) and Contact(s):
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Number: NCT03388619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s):
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Number: NCT03392181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Northwestern University|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Number: NCT03456843
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Yale University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Number: NCT03460977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Number: NCT03507608
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s):
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Number: NCT03556228
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): VM Oncology, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study to Evaluate CCS1477 in Advanced Tumours

Number: NCT03568656
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): CellCentric Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Number: NCT03569280
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kangpu Biopharmaceuticals, Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Phase I/II Study of OBI-3424 in Subjects With Advanced Solid Tumors

Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Number: NCT03619655
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)

Number: NCT03663218
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Number: NCT03674814
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Chicago|Corcept Therapeutics|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Number: NCT03706365
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s):
IMMU-132 in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Number: NCT03725761
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|National Cancer Institute (NCI)|Gilead Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s):
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Number: NCT03737370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tufts Medical Center|Bayer|Lahey Clinic|Henry Ford Hospital|Ohio State University Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Number: NCT03775525
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Genzada Pharmaceuticals USA, Inc.|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s):
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors

Number: NCT03784677
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Number: NCT03824652
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Number: NCT03824808
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): University of Missouri-Columbia
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Number: NCT03845166
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s):
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Number: NCT03873805
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Number: NCT03878524
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): OHSU Knight Cancer Institute|Oregon Health and Science University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s):
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients

Number: NCT03987217
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Utah|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seagen Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Number: NCT04038502
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development
Sponsor Trial Information
Trial Location(s) and Contact(s):
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Number: NCT04068896
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme LLC|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Number: NCT04100018
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Number: NCT04104776
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Constellation Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

Number: NCT04109729
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): University of Utah
Sponsor Trial Information
Trial Location(s) and Contact(s):
Stereotactic Magnetic Resonance Guided Radiation Therapy

Number: NCT04115254
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme LLC|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Number: NCT04140526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): OncoC4, Inc.|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s):
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Number: NCT04179864
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Epizyme, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors

Number: NCT04182516
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Nerviano Medical Sciences
Sponsor Trial Information
Trial Location(s) and Contact(s):
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Number: NCT04220983
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04221542
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s):
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Number: NCT04246671
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Bavarian Nordic
Sponsor Trial Information
Trial Location(s) and Contact(s):
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Number: NCT04249947
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Poseida Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
PK and Dose Escalation and Expansion Study of DST-2970

Number: NCT04291664
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): DisperSol Technologies, LLC|Translational Drug Development
Sponsor Trial Information
Trial Location(s) and Contact(s):
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Number: NCT04335682
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance Foundation Trials, LLC.|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s):
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Number: NCT04337580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

Number: NCT04349501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Diego
Sponsor Trial Information
Trial Location(s) and Contact(s):
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Number: NCT04363164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|United States Department of Defense
Sponsor Trial Information
Trial Location(s) and Contact(s):
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Number: NCT04388852
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer

Number: NCT04421222
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): ESSA Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04428788
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Celgene
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s):
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Number: NCT04457232
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme LLC|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Number: NCT04478279
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sapience Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Number: NCT04485013
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Tizona Therapeutics, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

Number: NCT04486755
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic

Number: NCT04497844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Number: NCT04503265
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): AtlasMedx, Incorporated
Sponsor Trial Information
Trial Location(s) and Contact(s):
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

Number: NCT04506567
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Number: NCT04514484
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Number: NCT04521686
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Eli Lilly and Company|Loxo Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer

Number: NCT04528199
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|FutureChem
Sponsor Trial Information
Trial Location(s) and Contact(s):
Jump: MR Simulation For Radiation Therapy Master Protocol

Number: NCT04545957
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of FT-7051 in Men With MCRPC

Number: NCT04575766
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Forma Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Re-treatment 225Ac-J591 for mCRPC

Number: NCT04576871
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Weill Medical College of Cornell University
Sponsor Trial Information
Trial Location(s) and Contact(s):
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Number: NCT04580485
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Incyte Corporation
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

Number: NCT04586335
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Haihe Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Number: NCT04592237
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s):
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Number: NCT04597359
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Number: NCT04606446
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Number: NCT04628988
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Celgene
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Number: NCT04631744
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s):
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Number: NCT04633252
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer

Number: NCT04644770
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Number: NCT04647526
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s):
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Number: NCT04660929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Carisma Therapeutics Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
ARX517 in Subjects With Advanced Solid Tumor

Number: NCT04662580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ambrx, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Number: NCT04666129
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Myovant Sciences GmbH
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Number: NCT04677855
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Number: NCT04689828
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resist

Number: NCT04691804
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Jiangsu HengRui Medicine Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Number: NCT04693377
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Number: NCT04698564
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s):
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Number: NCT04703920
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Michigan Rogel Cancer Center|Pfizer|Acrotech Biopharma LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Number: NCT04704505
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s):
TH1902 in Patients With Advanced Solid Tumors

Number: NCT04706962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Theratechnologies|PPD
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Number: NCT04709276
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew J. Armstrong, MD|Bristol-Myers Squibb|Duke University
Sponsor Trial Information
Trial Location(s) and Contact(s):
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Number: NCT04725903
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Number: NCT04726332
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s):
Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer

Number: NCT04729114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Propella Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma

Number: NCT04740034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Amgen
Sponsor Trial Information
Trial Location(s) and Contact(s):
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Number: NCT04743934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew McDonald|University of Alabama at Birmingham
Sponsor Trial Information
Trial Location(s) and Contact(s):
Abemaciclib With or Without Atezolizumab for mCRPC

Number: NCT04751929
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Dana-Farber Cancer Institute|Eli Lilly and Company|Genentech, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT04754191
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|Astellas Pharma Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Number: NCT04754425
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Number: NCT04768868
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Impact Therapeutics, Inc.|Covance
Sponsor Trial Information
Trial Location(s) and Contact(s):
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer

Number: NCT04777071
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Number: NCT04842890
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The New York Proton Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Number: NCT04844749
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Veru Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Number: NCT04846478
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Dana-Farber Cancer Institute|Epizyme, Inc.|Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s):
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Number: NCT04848337
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Ulka Vaishampayan|Merck Sharp & Dohme Corp.|University of Michigan|Hoosier Cancer Research Network
Sponsor Trial Information
Trial Location(s) and Contact(s):
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Number: NCT04857502
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Number: NCT04867603
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Norbert Avril, M.D.|Case Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Number: NCT04868604
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Clarity Pharmaceuticals Ltd
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Number: NCT04879940
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s):
225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC

Number: NCT04886986
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|POINT Biopharma
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Number: NCT04890613
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Senhwa Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Number: NCT04898634
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Number: NCT04925284
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s):
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Number: NCT04926181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Janssen Scientific Affairs, LLC|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s):
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer

Number: NCT04927663
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Michael Evans|U.S. Army Medical Research Acquisition Activity|National Institute of Mental Health (NIMH)|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

Number: NCT04931823
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Conjupro Biotherapeutics, Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC

Number: NCT04946370
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Weill Medical College of Cornell University|United States Department of Defense|Merck Sharp & Dohme LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Number: NCT04951492
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Number: NCT04957290
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Noxopharm Limited
Sponsor Trial Information
Trial Location(s) and Contact(s):
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Number: NCT04976257
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Ryan Kohlbrenner, MD|Radiological Society of North America|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s):
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Number: NCT04984343
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Viewray Inc.|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Number: NCT04986423
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Zenith Epigenetics|Astellas Pharma Inc|Newsoara Biopharma Co., Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s):
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Number: NCT04995198
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Prostate Cancer Clinical Trials Consortium|Memorial Sloan Kettering Cancer Center|Fred Hutchinson Cancer Center|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Advancing Cancer Treatment, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT05005728
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Xencor, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Number: NCT05010200
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ashutosh Kumar Tewari|Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s):
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT05011188
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Rahul Aggarwal|Fortis Therapeutics, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Number: NCT05022849
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of XmAb20717 in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Number: NCT05032040
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Xencor, Inc.|ICON plc
Sponsor Trial Information
Trial Location(s) and Contact(s):
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Number: NCT05037500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Roswell Park Cancer Institute|National Comprehensive Cancer Network
Sponsor Trial Information
Trial Location(s) and Contact(s):
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease

Number: NCT05045066
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
KZR-261 in Subjects With Advanced Solid Malignancies

Number: NCT05047536
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kezar Life Sciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Number: NCT05050084
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer

Number: NCT05053152
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Number: NCT05054296
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT05067140
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
EPI-7386 in Combination With Enzalutamide Compared With Enzalutamide Alone in Subjects With mCRPC

Number: NCT05075577
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): ESSA Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Number: NCT05081193
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clarus Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Number: NCT05113537
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Vadim S Koshkin|Prostate Cancer Foundation|Eli Lilly and Company|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s):
REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT05125016
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients

Number: NCT05156372
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

Number: NCT05156905
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of PRT2527 in Patients With Advanced Solid Tumors

Number: NCT05159518
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Prelude Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Number: NCT05160597
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial

Number: NCT05168618
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Utah|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Number: NCT05169684
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Bristol-Myers Squibb
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

Number: NCT05169970
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Number: NCT05176483
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Exelixis
Sponsor Trial Information
Trial Location(s) and Contact(s):
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Number: NCT05177042
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Number: NCT05204927
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Curium US LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Number: NCT05215574
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): NGM Biopharmaceuticals, Inc|Merck Sharp & Dohme LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Targeted Alpha Therapy With 225Actinium-PSMA-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Number: NCT05219500
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Excel Diagnostics and Nuclear Oncology Center
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Number: NCT05241613
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Accutar Biotechnology Inc
Sponsor Trial Information
Trial Location(s) and Contact(s):
PET Imaging Study of 89Zr-DFO-YS5

Number: NCT05245006
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Robert Flavell, MD, PhD|United States Department of Defense|Fortis Therapeutics, Inc.|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s):
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

Number: NCT05249127
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Clarity Pharmaceuticals Ltd
Sponsor Trial Information
Trial Location(s) and Contact(s):
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Number: NCT05252390
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Nuvation Bio Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Number: NCT05268666
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Jubilant Therapeutics Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Number: NCT05288166
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Number: NCT05293496
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Number: NCT05311618
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): NGM Biopharmaceuticals, Inc|Merck Sharp & Dohme LLC
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Number: NCT05348577
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s):
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer

Number: NCT05369000
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Lava Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s):
Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

Number: NCT05396872
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Number: NCT05413421
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): ORIC Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s):
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Number: NCT05413850
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Blue Earth Therapeutics Ltd|PSI CRO
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

Number: NCT05415098
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Number: NCT05441501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Number: NCT05479578
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Rashmi Verma, MD|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Number: NCT05489211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Number: NCT05489991
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Number: NCT05519449
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
MGC018 Versus Androgen Receptor Axis-targeted Therapy in Participants With Metastatic Castration Resistant Prostate Cancer

Number: NCT05551117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2|Phase 3
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Number: NCT05585034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Number: NCT05588609
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s):
Sponsor Trial Information
Trial Location(s) and Contact(s):

Total: 206 Clinical Trials













PHEN,Inc. © 2023 All rights reserved